# Engineering B Cells With Immusoft's Sean Ainsworth Page: https://stenobird.com/podcast/business-of-biotech-123501/engineering-b-cells-with-immusoft-s-sean-ainsworth Text version: https://stenobird.com/podcast/business-of-biotech-123501/engineering-b-cells-with-immusoft-s-sean-ainsworth.md Podcast: [Business Of Biotech](https://stenobird.com/podcast/business-of-biotech-123501) Published: 2025-12-08T11:00:00+00:00 Episode link: https://www.buzzsprout.com/1011661/episodes/18292145-engineering-b-cells-with-immusoft-s-sean-ainsworth.mp3 Audio file: https://www.buzzsprout.com/1011661/episodes/18292145-engineering-b-cells-with-immusoft-s-sean-ainsworth.mp3 Processing state: not_requested JSON: https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/engineering-b-cells-with-immusoft-s-sean-ainsworth Duration seconds: 3231 ## Resource We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell therapies offer a better, more patient-friendly administration for lysosomal storage diseases currently treated with enzyme replacement therapies. Sean also discusses FDA pathways, incentives, and agen... ## Actions - request_transcript: `POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/engineering-b-cells-with-immusoft-s-sean-ainsworth/transcription-requests` — Idempotently request low-priority transcript generation for this episode. - read_markdown: `GET https://stenobird.com/podcast/business-of-biotech-123501/engineering-b-cells-with-immusoft-s-sean-ainsworth.md` — Read the agent-friendly Markdown representation of this episode resource. A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed. ## Transcript Full transcripts are not published on public pages unless there is a clear rights basis.